A carregar...
Taking a “BiTE out of ALL”: blinatumomab approval for MRD-positive ALL
Blinatumomab, a bispecific T-cell engager (BiTE) associated with improved survival in relapsed or refractory acute lymphoblastic leukemia (ALL), was recently approved for treatment of minimal residual disease (MRD). MRD is an important predictor of survival in ALL, and recent studies suggest that ac...
Na minha lista:
| Publicado no: | Blood |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Hematology
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6634959/ https://ncbi.nlm.nih.gov/pubmed/30796026 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-12-852376 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|